Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Resistance news

Show

From To
AZT resistance suppression mutations can also reduce tenofovir resistance, test tube study shows (corrected)

This is a corrected version of an article originally published on aidsmap.com on Friday, 19 November 2004. Mutations in HIV that suppress AZT (zidovudine, Retrovir) resistance,

Published
19 November 2004
By
Christopher Gadd
High resistance levels seen in treated Ugandans: cost of therapy blamed

One-third of a group of 137 patients at Mulago Hospital in Kampala, Uganda had failed antiretroviral therapy after an average follow-up period of 38 weeks,

Published
18 November 2004
By
Gus Cairns
Infection with multi-drug resistant virus is lifelong, Canadian expert argues

Patients infected with HIV resistant to all three widely used classes of antiretrovirals will keep that resistance for life, and not revert back to wild

Published
17 November 2004
By
Gus Cairns
Failure of three main classes of antiretrovirals present in 12% of EuroSIDA cohort

Nearly 13% of individuals taking HAART in a major observational cohort have experienced the failure of all of the three main classes of antiretroviral drugs,

Published
15 November 2004
By
Michael Carter
Core group of patients with drug resistant HIV engaging in risky sex identified by US study

A small minority of HIV-positive patients taking highly active antiretroviral therapy (HAART) have drug resistance and engage in unprotected anal or vaginal sex with partners

Published
11 November 2004
By
Michael Carter
ICAAC: Resistance found in one in seven of treatment-naive US patients

Around one in seven of a large sample of treatment-naïve HIV-positive Americans from 40 cities showed evidence of resistance to at least one antiretroviral drug,

Published
31 October 2004
By
Keith Alcorn
Two-thirds of PI-experienced children fail on lopinavir and accumulate resistance mutations

A French study of 69 children treated with the protease inhibitor (PI) lopinavir/ritonavir (Kaletra) found that two-thirds of children who had failed on other PIs

Published
08 October 2004
By
Gus Cairns
Drug resistance: up to fivefold difference in risk of transmission of different mutations, Spanish estimate

There appears to be a wide variation in the transmissibility of drug-resistant HIV according to the specific drug-resistance mutation it carries, Spanish researchers report in

Published
04 October 2004
By
Gus Cairns
Rare case of lopinavir resistance in first line treatment reported

A rare case of resistance to the protease inhibitor lopinavir has been published in a case report in the September 24th edition of AIDS. Even

Published
27 September 2004
By
Michael Carter
Poor levels of T-20 seen in semen of HIV-positive men

Concentrations of the fusion inhibitor T-20 (enfuvirtide, Fuzeon) in the genital tract are suboptimal, risking the development of resistant HIV, according to a small French

Published
09 September 2004
By
Michael Carter

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.